New drug cocktail shows promise for myeloma patients ineligible for transplant

NCT ID NCT04009109

Ongoing Disease control Sponsor: Alliance Foundation Trials, LLC. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of four drugs (lenalidomide, ixazomib, dexamethasone, and daratumumab) in 79 adults newly diagnosed with multiple myeloma who cannot have a stem cell transplant. Participants receive the drugs for 12 cycles, then are split into two groups: one continues with lenalidomide alone, the other with three drugs, both for up to 2 years. The goal is to see which approach better delays the cancer's return or worsening.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOMA MULTIPLE

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Gibbs Cancer Center & Research Institute/Spartanburg Regional Healthcare

Spartanburg, South Carolina, 29303, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Northern Light Eastern Maine Medical Center

Bangor, Maine, 04401, United States
SUNY Upstate Medical Center

Syracuse, New York, 13210, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68152, United States
University of North Carolina

Chapel Hill, North Carolina, 27514, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.